QuidelOrtho Q1 revenue $693M, +5% ex-COVID/Donor; adjusted EPS $0.74 vs $0.44 YoY

QuidelOrtho Corp

2025-Q1 EPS reported -$0.19 revenue$692,800,000

Total revenue $693M, -3% reported due to lower COVID/Donor; ex-COVID/Donor +5% as reported and +6% constant currency.
GAAP operating margin improved to 5% from (247%); adjusted EBITDA margin 23%, +450 bps driven by cost-savings.
GAAP diluted loss per share $0.19 vs $25.50 loss prior (which included $1.74B goodwill impairment); adjusted EPS $0.74 vs $0.44.
Labs revenue grew 5% as reported (7% constant currency); Donor Screening declined 62% as business winds down.
Full-year 2025 guidance maintained: revenue $2.60-$2.81B, adjusted EBITDA $575-615M, adjusted diluted EPS $2.07-$2.57.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.